All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis Farma S.p.A Viale Luigi Sturzo, 43 - 20154 Milano (MI) tel. 02/9654.1 ...

Chef de produit junior oncologie (tumeurs solides) en stage Early Career (Fixed Term), Full time Marketing Frankreich Paris Headquarter (Novartis Pharma S.A.S.) Dez 16, 2025 ...

Patient Engagement Therapeutic Area Manager Regular, Full time Development United Kingdom +Alternative Locations London (The Westworks) dez 16, 2025 ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt ...

Sports have a universal appeal that transcends boundaries. Each weekend, the National Football League (NFL) ignites millions of passionate fans from across the country, demonstrating the deep ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

All Canadians deserve the same access to quality care. Novartis Canada believes health equity starts with listening to communities and supporting local solutions. That’s why we are committed to ...

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...